The
global IVD quality
control market size is expected to reach USD 1.24 billion by 2026,
according to a new report by Grand View Research, Inc. The market is projected
to witness a CAGR of 4.1% over the forecast period. Continually evolving
technology-oriented changes in the diagnostics field and growing need to ensure
patient safety necessitate the implementation of quality assurance programs in
various medical disciplines including radiology and Point-of-Care (PoC)
devices. Patients rely on self-testing IVD devices for long-term disease
management and hence it is important for such devices to be checked, in terms
of result reproducibility and validity, to guarantee patient safety.
Rising
number of certified clinical laboratories offering dependable IVD-based
diagnostic services directly correlates with increased patient confidence, thus
driving the market. In addition to quality assessments, amendments to the
regulatory framework are made intermittently to enhance the existing standards
with the main objective of safeguarding qualitative superiority of the
diagnostic services. In May 2016, the European Union passed an agreement to
update the pre-existing regulations pertaining to IVD devices, wherein the
updates were in concern with raising the patient safety levels, particularly
for disabled persons. The presence of third-party agencies for independent
assessment of the IVD devices is expected to elevate the current safety
standards, which will drive the In Vitro Diagnostics (IVD) Quality Control
market further.
Related Press Release@ https://www.grandviewresearch.com/industry-analysis/in-vitro-diagnostics-ivd-quality-control-market
Further key findings from the study suggest:
- In 2018, the
clinical chemistry was the second-largest application segment of the
global IVD market, in terms of market share
- Demand for
preventive medicine and rapid transformation of clinical laboratories into
highly automated and efficient businesses are some of the factors for the
segment’s growth
- Molecular diagnostics
is projected to be the fastest-growing segment due to increasing technical
complexity of molecular diagnostic testing and need for quality evaluation
to ensure standards
- These tests
are of prime importance as the outcomes enable healthcare practitioners
make critical treatment decisions
- Hospitals
was the largest segment in 2018 due to the presence of advanced
technology-based devices like Next Generation Sequencing (NGS) and
microarrays, and rising applications of the optimized quality-control procedures
- North
America was the dominant regional market in 2018 due to the presence of
over 150,000 registered diagnostics labs and is likely to maintain the
dominance throughout the forecast years
- Siemens
Healthcare GmbH; Roche Diagnostics; Alere, Inc.; Abbott Laboratories,
Inc.; Qiagen N.V.; Bio-Rad Laboratories, Inc.; Quidel Corp.; Becton,
Dickinson and Company; bioMerieux, Inc.; Sysmex Corp.; Sero AS; and Thermo
Fisher Scientific, Inc. are some of the key companies in the global market
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment